SEARCH

SEARCH BY CITATION

References

  • 1
    Langholz E, Munkholm P, Nielsen OH, et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991; 26: 124756.
  • 2
    Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962–87: a sixfold increase in incidence. Scand J Gastroenterol 1992; 27: 60914.
  • 3
    Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 6907.
  • 4
    Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen city and county, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 127482.
  • 5
    Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 8307.
  • 6
    Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99: 4436.
  • 7
    Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990; 99: 98794.
  • 8
    Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis 2009; 15: 258.
  • 9
    Bortoli A, Saibeni S, Tatarella M, et al. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol 2007; 22: 5429.
  • 10
    Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy. Inflamm Bowel Dis 2009; 15: 10448.
  • 11
    Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol 2002; 97: 6418.
    Direct Link:
  • 12
    Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn’s disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 242630.
  • 13
    Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 917.
  • 14
    Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 238592.
    Direct Link:
  • 15
    Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease – a population-based cohort study. Am J Obstet Gynecol 1997; 177: 9426.
  • 16
    Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 110612.
  • 17
    Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 65661.
  • 18
    Norgard B, Puho E, Pedersen L, et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol 2003; 98: 200610.
  • 19
    Norgard B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with Crohn’s disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007; 102: 194754.
    Direct Link:
  • 20
    Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25: 2715.
  • 21
    Woolfson K, Cohen Z, McLeod RS. Crohn’s disease and pregnancy. Dis Colon Rectum 1990; 33: 86973.
  • 22
    Raatikainen K, Mustonen J, Pajala MO, et al. The effects of pre- and post-pregnancy inflammatory bowel disease diagnosis on birth outcomes. Aliment Pharmacol Ther 2011; 33: 3339.
  • 23
    Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 73542.
  • 24
    Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in Crohn’s disease. Scand J Gastroenterol 1984; 19: 72432.
  • 25
    Norgard B, Fonager K, Sorensen HT, et al. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000; 95: 316570.
    Direct Link:
  • 26
    Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006; 55: 1198206.
  • 27
    Nielsen MJ, Norgaard M, Holland-Fisher P, et al. Self-reported antenatal adherence to medical treatment among pregnant women with Crohn’s disease. Aliment Pharmacol Ther 2010; 32: 4958.
  • 28
    van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4: 493510.
  • 29
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 30
    Jowett SL, Seal CJ, Phillips E, et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003; 38: 16471.
  • 31
    Van AG, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohn’s Colitis 2010; 4: 63101.
  • 32
    Biancone L, Michetti P, Travis S, et al. for the European Crohn’s and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008; 2: 6392.
  • 33
    Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut 2006; 55(Suppl 1): i3658.
  • 34
    Habal FM, Ravindran NC. Management of inflammatory bowel disease in the pregnant patient. World J Gastroenterol 2008; 14: 132632.
  • 35
    Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 7338.
  • 36
    Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn’s disease. Am J Gastroenterol 2001; 96: 22745.
  • 37
    Gray LE Jr, Ostby J, Furr J, et al. Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicol Sci 2000; 58: 35065.
  • 38
    Kaiser J. Toxicology. Panel finds no proof that phthalates harm infant reproductive systems. Science 2005; 310: 422.
  • 39
    Swan SH, Main KM, Liu F, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 2005; 113: 105661.